We’ve recently updated our valuation analysis.

Bio-Rad Laboratories Valuation

Is BIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIO?

Other financial metrics that can be useful for relative valuation.

BIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.2x
Enterprise Value/EBITDA16.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BIO's PS Ratio compare to its peers?

BIO PS Ratio vs Peers
The above table shows the PS ratio for BIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average5.1x
AVTR Avantor
1.8x4.3%US$13.9b
TECH Bio-Techne
10.3x11.5%US$11.4b
WAT Waters
5.6x5.2%US$16.4b
CRL Charles River Laboratories International
2.6x9.2%US$9.5b
BIO Bio-Rad Laboratories
4.3x5.0%US$12.5b

Price-To-Sales vs Peers: BIO is good value based on its Price-To-Sales Ratio (4.3x) compared to the peer average (5.1x).


Price to Earnings Ratio vs Industry

How does BIO's PE Ratio compare vs other companies in the US Life Sciences Industry?

Price-To-Sales vs Industry: BIO is expensive based on its Price-To-Sales Ratio (4.3x) compared to the US Life Sciences industry average (3.7x)


Price to Sales Ratio vs Fair Ratio

What is BIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.3x
Fair PS Ratio4.1x

Price-To-Sales vs Fair Ratio: BIO is expensive based on its Price-To-Sales Ratio (4.3x) compared to the estimated Fair Price-To-Sales Ratio (4.1x).


Share Price vs Fair Value

What is the Fair Price of BIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIO ($414.52) is trading below our estimate of fair value ($513.31)

Significantly Below Fair Value: BIO is trading below fair value, but not by a significant amount.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies